FDA Directors Discuss EUAs, Transparency, and COVID-19

In a recent meeting, Food and Drug Administration directors discussed how emergency use authorizations (EUAs) affected the response to the COVID-19 pandemic. FDA officials also discussed possible changes to the EUA mechanism.

“The flexibility of emergency use authorizations, and allowing the FDA to accept more uncertainty during the pandemic so far, has ultimately aided its response to COVID-19, center directors said Tuesday at a workshop at the National Academies of Sciences, Engineering and Medicine. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, pointed to the agility of the EUAs, and the ability to quickly revoke any EUAs, as well as the transparency around those decisions as to what led to the evolution of the types of therapeutics that have been authorized.” Read more here.

(Zachary Brennan, Endpoints News, 10/6/21)